Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

Xiaojun Xu

Status: Not yet enrolling

Conditions: Acute Lymphoblastic Leukemia, Pediatric

Treatments: Drug: Blinatumomab

Study type: Observational

Funder types: Other

Identifiers

NCT05837689

2023-IRB-0062-P-01

Details and patient eligibility

About

A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next generation sequencing (NGS). The efficacy of blinatumomab clearing MRD detected by NGS will be analyzed, in order to see the potential of using NGS to guide MRD eradication by blinatumomab.

Enrollment: 20 estimated patients

Sex: All

Ages: 1 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with B cell precursor acute lymphoblastic leukemia
• Patients who received blinatumomab for consolidation
• Patients who were detected MRD positive by NGS before initiation of blinatumomab treatment

Exclusion criteria

• Patients without data of NGS detection after receiving blinatumomab treatment